Circulating adiponectin: a cardiometabolic marker associated with global cardiovascular risk
- Authors: Di Chiara,T;Argano,C;Scaglione,A;Corrao,S;Pinto,A;Scaglione,R
- Publication year: 2015
- Type: Articolo in rivista (Articolo in rivista)
- OA Link: http://hdl.handle.net/10447/125152
OBJECTIVE This study was designed to evaluate the relationship among circulating adiponectin (ADPN), left ventricular mass (LVM) and cardiometabolic comorbidities in subjects at higher global cardiovascular risk (score of “ Cuore Project “) METHODS. 115 consecutive subjects were grouped according to normal or low ADPN levels. Left ventricular internal diameter (LVID/h), total LV mass (LVM), LVM index (LVMI), relative wall thickness (RWT), LV ejection fraction by echocardiography and diastolic parameters, by pulsed-wave Doppler were calculated. RESULTS Low-ADPN subjects were characterized by a significant higher prevalence of some cardiometabolic comorbidities (obesity, visceral obesity, diabetes and insulin resistance, LVH, Metabolic syndrome ( MetS),CAD). BMI (p<0.0001), WHR (p<0.03), triglycerides (p<0,001), HOMA-IR (p<0.001), LVM, LVMI, IVST and RWT (p< 0.0001) were significantly increased and HDL-C (p<0.001) and LVEF were significantly reduced in low-ADPN than normal-ADPN subjects. LVMI correlated directly with BMI (p<0.001), WHR (p<0.001) MBP (p<0.001), MetS (p<0.001) and inversely with ADPN ( p<0.0001). Mutiple regression analysis indicated that ADPN was independently associated to LVMI. CONCLUSIONS ADPN might be considered a key component that mediates the cross-talk between adipose tissue, cardiac cells and the vasculature. Accordingly, its routine measurement might become a new target in the management of global CV risk .